Boston, 12 January 2026: SERB Pharmaceuticals, a global speciality pharmaceutical company focused on rare diseases and medical emergencies, has appointed Dr Peter C. Adamson, MD, FASCO, to its US Board as a Non-Executive Director.
Dr. Adamson being exceptional credentials as a globally recognized physician-scientist and leader in oncology drug development and clinical pharmacology. Dr Adamson currently serves as Global Head of Oncology Clinical Department at Servier and is Professor Emeritus at the University of Pennsylvania Perelman School of Medicine. This appointment reflects SERB’s ongoing investment in scientific expertise as it accelerates growth in rare oncology.
“Peter’s appointment reflects SERB’s commitments to scaling up our medical and scientific leadership, especially as we continue to advance treatments for rare and difficult to treat cancers,” said Vanessa Wolfeler, CEO of SERB Pharmaceuticals. “We look forward to having his expertise and perspective to help guide our journey.”
Dr Adamson is internationally recognized for his leadership in oncology drug development and pediatric cancer research. His career spans significant roles including the Alan R. Cohen Endowed Chair of the Children’s Oncology Group. He has also played a pivotal role in shaping US cancer policy through his service on the National Cancer Advisory Board and the NCI Blue Ribbon Panel for the Cancer Moonshot Initiative. In 2023, he received the American Society of Clinical Oncology (ASCO) Pediatric Award.
About SERB Pharmaceuticals
SERB is a global speciality pharmaceutical company with a growing portfolio of medicines for rare emergency medicine, rare diseases, and CBRN preparedness. For over 30 years we have consistently provided emergency medicines, medical countermeasures, and the world’s leading portfolio of antidotes. With a strong presence in the US, Europe, and the Middle East, along with a global network of distribution partners, we make essential medicines available in over 100 countries. Our proven ability to acquire, develop, manufacturer, launch and commercialize specialist medicines allows us to meet critical medical needs with urgency. By expanding our reach through selective acquisitions and entering new markets, we’re not just supplying medicine, we’re improving the standards for more patients around the world.
Learn more at https://SERB.com.
For further information contact:
SERB Pharmaceuticals: Chris Sampson, Corporate Communications Director
chris.sampson@serb.com; Tel: +44 (0)7773 251 178
